Compare NAII & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | PASG |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | 24 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 12.8M |
| IPO Year | 1995 | 2020 |
| Metric | NAII | PASG |
|---|---|---|
| Price | $1.09 | $3.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 22.8K | 13.8K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $132,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.60 | N/A |
| 52 Week Low | $1.06 | $3.29 |
| 52 Week High | $4.96 | $20.00 |
| Indicator | NAII | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 54.57 |
| Support Level | $1.08 | $3.30 |
| Resistance Level | $2.52 | $5.03 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 24.55 | 98.36 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.